news
Women report stronger psychedelic trips than men at equal doses
Recent clinical trials evaluating psilocybin show women consistently score higher on subjective drug intensity and altered perception than men given equivalent weight-adjusted doses. Researchers suspect differences in estrogen modulation of serotonin 5-HT2A receptor density and metabolic breakdown in the liver explain the gap. The findings suggest clinical trials need sex-specific titration rather than flat milligrams per kilo.
Recent clinical trials evaluating psilocybin show women consistently score higher on subjective drug intensity and altered perception than men given equivalent weight-adjusted doses. Researchers suspect differences in estrogen modulation of serotonin 5-HT2A receptor density and metabolic breakdown in the liver explain the gap. The findings suggest clinical trials need sex-specific titration rather than flat milligrams per kilo.
The architecture take
Clinical psychedelics spent a decade treating body weight as the only variable that mattered for dosing, which was lazy pharmacology. I remember talking to a trial coordinator two years ago who admitted offhand that female participants routinely reported deeper visual distortion and heavier emotional turbulence on standard 25 mg psilocybin doses. The mechanism is starting to clear up. Circulating estradiol directly alters 5-HT2A receptor sensitivity in the prefrontal cortex, while liver enzymes like CYP2D6 clear active metabolites at different rates across sexes. Giving a 60-kilo woman and a 60-kilo man the identical protocol assumes their serotonin pathways run on the same baseline calibration. They do not. When therapy clinics charge $3,000 a session to guide someone through an ego-dissolving afternoon, sending one demographic into orbit while another barely lifts off is bad practice. Watch psychedelic drug developers quietly split their phase-three dosage arms by sex before regulators force their hand.